April 11, 2011
CASE CCC IN THE NEWS
New Cancer Center is a First for Region
UH Cancer Center Unites Care, Eases Capacity Concern
Editing-molecule Mutation Causes Fatal Primordial Dwarfism
Is Your Child's Headache Actually a Brain Tumor?
UH Seidman Cancer Center to Offer Cutting-edge Care
Study Suggests Wider Role for Neoadjuvant Chemo in Ovarian Cancer
Today's Health: Radiation dangers
MARK YOUR CALENDARS
Cancer Center Seminar Series: Development of Targeted Therapy for ERK Pathway in Triple-Negative Breast Cancer
Friday, April 15
Please join us Friday, April 15 at the next Cancer Center Seminar Series featuring Chandra Bartholomeusz, MD, PhD. Dr. Bartholomeusz, Assistant Professor of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center, will present Development of Targeted Therapy for ERK Pathway in Triple-Negative Breast Cancer.
Dr. Bartholomeusz has been faculty in the Department of Breast Medical Oncology-Research at the University of Texas MD Anderson Cancer Center since 2009. Her research focuses on the MAPK pathway, particularly the role of ERK in Triple-negative breast cancer, with an emphasis on developing ERK as a therapeutic target for inhibiting tumorigenicity and metastasis. She has used proteomics and siRNA technology to further probe the mechanism of ERK pathway in tumor suppression. These studies will provide a basis for the further understanding of ERK and its implications for the design of more effective targeted therapies. This comprehensive approach will be applied to other groups of interacting genes discovered by siRNA screening during the multifaceted approach in understanding the biological mechanisms to therapeutic interventions.
Special Cancer Center Seminar Series: Thioredoxin-1, a Molecular Switch Modulating TGF-β-mediated Epithelial to Mesenchymal Transition
Friday, April 15
Immediately following the presentation by Dr. Chandra Bartholomeusz, please join us for a Special Cancer Center Seminar Series featuring Geoffrey Bartholomeusz, PhD, Assistant Professor of Experimental Therapeutics at the University of Texas MD Anderson Cancer Center. Dr. Bartholomeusz will present Thioredoxin-1, a Molecular Switch Modulating TGF-β-mediated Epithelial to Mesenchymal Transition.
Dr. Bartholomeusz's research focuses on understanding the functioning of key signaling pathways such as EGFR, JAK/Stat and Bcr-Abl associated with tumorigenesis in breast, pancreatic and hematopoietic malignancies. His current research focuses on understanding the role of the redox regulator Thioredoxin-1 in tumor proliferation and metastasis. Using a high throughput RNAi screen, he has identified thioredoxin-1 as a component of TGF-beta dependent signaling in both pancreatic and breast cancer cells, and that thioredoxin-1 may function as a modulator of TGF-beta dependent tumor growth and epithelial to mesenchymal transition. His goal is to develop effective targeted therapies of thioredoxin-1 signaling to either inhibit tumor growth and/or inhibit tumor metastasis. His desire to identify small molecules with effective anti-tumor activity has led him to develop a 3D in vitro cell culture model that can be used for high throughput drug screens. His goal is to develop a co-culture 3D model system utilizing either cell lines or primary tumors with the objective of creating a heterogeneous microenvironment for drug screens. His results have been presented nationally and internationally, and have resulted in peer-reviewed publications, including publications in PNAS, Cancer Research, Blood, Journal of Biological Chemistry and Cancer Cell. He is the current recipient of a Cancer Prevention and Research Institute of Texas (CPRIT) Award for 5 years.
Case CCC Scientific Series
The next installment of the Case CCC Scientific Series is scheduled for Thursday, April 21 from 4-6:30 pm in Wolstein Auditorium (WRB 1-413). Drs. Anton Gorbachev, Neetu Gupta and Alex Huang will discuss the topic of Immunology. Presentations will be followed by a short receptions. All are encouraged to attend.
Case CCC Annual Scientific Retreat
The Case CCC Annual Scientific Retreat will be July 8-9 at Corporate College East. Details will be posted soon.
Pilot Project Grants: American Cancer Society IRG Awards
The Case CCC is currently accepting applications for American Cancer Society Institutional Research Grant (IRG) awards. Pilot funding is available for projects in basic, clinical, prevention and control, behavioral, health services, and epidemiology cancer research with awards up to $30,000 for one-year cancer research projects that provide the basis for future independent grants.
IRG pilot project grants are intended to support independent, self-directed investigators early in their careers (assistant professor or equivalent). Applicants for the pilot project grants should be within 6 years of their first independent research or faculty appointment and eligible to apply for an independent national competitive research grant, but may not currently hold such a grant.
At the time of application, recipients of IRG pilot project grants must be citizens or noncitizen nationals of the United States or its possessions and territories, or must have been lawfully admitted to the United States for permanent residence at the time of application.
Instructions, frequently asked questions, and application forms are available at http://cancer.case.edu. Contact Terri Daso, Cancer Center Administration (844-7252, email@example.com) for more information.
LOI Deadline: June 13
Ovarian Cancer Research Fund
The Ovarian Cancer Research Fund has released a call for applications for the following opportunities:
Program Project Development Grants ($900,000) provide funds for ovarian cancer research projects that may involve several investigators within one institution or collaborations between groups in multiple institutions.
Liz Tilberis Scholars awards ($450,000) are for junior investigators in their first academic faculty appointment. This award is open to physician-scientists (Gynecologic Oncology, Medical Oncology) and PhD scientists.
Ann Schreiber Research Training Programs of Excellence grant ($75,000) funds post-doctoral trainees (Gynecologic Oncology or Medical Oncology fellows or PhDs) who are working in established ovarian cancer research groups.
LOI Deadline: May 9
NCI Professional Budget Judgement: The Nation's Investment in Cancer Research
As required by statute, each year the NCI prepares for the President and Congress its best professional judgment budget on the optimum funding needed to make the most rapid progress against cancer. The Professional Judgment Budget for 2012, Cancer: Changing the Conversation, is now available on NCI's Web site for public reference. The purpose of this document is to spark a broader conversation about the Nation's investment in cancer research.
Member Sites Selected for Cancer Immunotherapy Trials Network
The Case CCC, with Dr. Pierre Triozzi as PI, is one of 27 sites that will be participating in the new Cancer Immunotherapy Trials Network (CITN). The CITN will conduct multicenter research on agents that boost patients' own immune systems to fight their cancer. By coordinating the efforts of academia, industry, and philanthropic foundations, the CITN is charged with accelerating the development of promising agents that have already been discovered but are not currently used to treat patients with cancer.
An open competition was held for institutions to apply for member site status in the CITN, and immunotherapy experts evaluated candidates on the experience, participation, and collaboration of the investigators and their institutions in immunotherapy trials and their ability to provide laboratory expertise in tumor immunology to support the trials.
An initial meeting of CITN investigators is scheduled for May 9-10 in Bethesda, MD, to discuss the operations of the CITN and to introduce the first concepts to be studied by this new cancer immunotherapy program.
Details are available in the latest NCI Cancer Bulletin.
ACS Grantee Newsletter Winter 2010/2011
The latest edition of the ACS Grantee Newsletter Winter 2010/2011 is now available. Highlights include:
**All events are open to anyone interested in attending
Pathology Research Seminar
Ford Distinguished Lecture
Pathology Graduate Student Seminar
DNA Repair Inhibition Journal Club
Stem Cell Biology and Regenerative Medicine Seminar
Taussig Cancer Institute Grand Rounds canceled
Cancer Center Seminar Series
Immunology Faculty Research in Progress Series
Special Cancer Center Seminar Series
Cancer Center Research in Progress Seminar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
Breast Cancer Detection and Management: Issues for 2011
Case CCC Annual Scientific Retreat
ADDITIONAL UPCOMING SEMINARS & EVENTS
Fourth Annual Translational to Clinical (T2C) Wound Care Conference
Midwest Blood Club 9th Annual Symposium
2011 Clinical and Translational Research and Education Meeting: ACRT/SCTS Joint Annual Meeting
Cincinnati Cancer Symposium Series: 2011 Symposium on NF-κB, Cancer, Obesity, and Inflammation
4th International Symposium on Cancer Metastasis and the Lymphovascular System
2nd Annual Department of Medicine Research Day
Race for the Place
International Society for Stem Cell Research (ISSCR) Annual Meeting
Cancer Health Disparities Summit 2011
8th International Conference of the Society for Integrative Oncology: Innovating Integrative Oncology: New Science, New Solutions
NCI CANCER BULLETIN
April 5, 2011
PREVIOUSLY ANNOUNCED FUNDING OPPORTUNITIES
Avon Foundation Breast Cancer Research Program
AACR Scholar-in-Training Awards - Other Conferences and Meetings
NIH BULLETIN – Notices and Funding Opportunities
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to firstname.lastname@example.org.